The synthesis of a selective PDE4/TNFα inhibitor

被引:34
|
作者
Caron, S [1 ]
Vazquez, E [1 ]
机构
[1] Pfizer Global Res & Dev, Chem Res & Dev, Groton, CT 06340 USA
关键词
D O I
10.1021/op010223p
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Two syntheses of cis-4-cyano-4-(1-cyclohexyl-3-ethyl-1H-indazol-6-yl)cyclohexanecarboxylic acid (1), a selective PDE4/TNF alpha inhibitor are described. The first synthesis relied on a solvolysis of a tertiary benzylic alcohol to the nitrile using TMSCN and on the epimerization of an ester to its thermodynamically favored position prior to its hydrolysis. It was demonstrated that the selectivity was controlled by the rate of hydrolysis of the two diastereomeric esters. The second synthesis proved to be more efficient and used a novel nucleophilic aromatic substitution of a fluoroindazole with the anion of a tertiary nitrile. Another key element of the route was a selective Pinner reaction of a secondary nitrile in the presence of a tertiary nitrile.
引用
收藏
页码:587 / 592
页数:6
相关论文
共 50 条
  • [21] Implications of PDE4 structure on inhibitor selectivity across PDE families
    H Ke
    International Journal of Impotence Research, 2004, 16 : S24 - S27
  • [22] Asymmetric Total Synthesis and Biological Evaluation of the Natural PDE4 Inhibitor Toddacoumalone
    Hou, Ke-Qiang
    Chen, Xue-Ping
    Huang, Yiyou
    Chan, Albert S. C.
    Luo, Hai-Bin
    Xiong, Xiao-Feng
    ORGANIC LETTERS, 2020, 22 (02) : 584 - 588
  • [23] Implications of PDE4 structure on inhibitor selectivity across PDE families
    Ke, H
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2004, 16 (Suppl 1) : S24 - S27
  • [24] PHOSPHODIESTERASES 4 (PDE4) INHIBITOR AMELIORATES EXPERIMENTAL ARTHRITIS
    Chen, W.
    Xu, Z.
    Wee, H.
    Lewis, G. S.
    Olsen, N.
    Lin, J.
    Zheng, S. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 270 - 270
  • [25] Design, Synthesis, and Evaluation of Selective PDE4 Inhibitors for the Therapy of Pulmonary Injury
    Li, Mengjie
    Li, Gang
    Liu, Yuanhui
    Li, Jiayu
    Ou, Yanghui
    Guan, Wen
    Zeng, Zhijun
    Tang, Haiyang
    Bai, Dan
    Zhang, Guoping
    Huang, Peiming
    Song, Liyan
    Ye, Lianbao
    Ke, Hengming
    Yao, Hongliang
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 3837 - 3857
  • [26] Orally active PDE4 inhibitor with therapeutic potential
    Ochiai, H
    Ohtani, T
    Ishida, A
    Kishikawa, K
    Yamamoto, S
    Takeda, H
    Obata, T
    Nakai, H
    Toda, M
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2004, 39 (07) : 555 - 571
  • [27] T-440 - Antiasthmatic PDE4 inhibitor
    不详
    DRUGS OF THE FUTURE, 2001, 26 (07) : 717 - 718
  • [28] Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor
    Zhang, Qiangnan
    Durig, Thomas
    Blass, Benjamin
    Fassihi, Reza
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 615
  • [29] Pharmacology of a Novel, Orally Active PDE4 Inhibitor
    Dastidar, Sunanda G.
    Ray, Abhijit
    Shirumalla, Rajkumar
    Rajagopal, Deepa
    Chaudhary, Shiwani
    Nanda, Kamna
    Sharma, Pawan
    Seth, Mahesh Kumar
    Balachandran, Sarala
    Gupta, Nidhi
    Palle, Venkata
    PHARMACOLOGY, 2009, 83 (05) : 275 - 286
  • [30] Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis
    Abdulrahim, Hunar
    Thistleton, Samuel
    Adebajo, Adewale O.
    Shaw, Tim
    Edwards, Christopher
    Wells, Alvin
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (07) : 1099 - 1108